Cargando…
Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers
BACKGROUND: Dengue is a growing global health threat with no specific antiviral drugs available for treatment or prophylaxis. This first-in-human, double-blind, randomized, placebo-controlled study aimed to examine the safety, tolerability, and pharmacokinetics of increasing single and multiple oral...
Autores principales: | Ackaert, Oliver, Vanhoutte, Frédéric, Verpoorten, Nathalie, Buelens, Annemie, Lachau-Durand, Sophie, Lammens, Lieve, Hoetelmans, Richard, Van Loock, Marnix, Herrera-Taracena, Guillermo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506772/ https://www.ncbi.nlm.nih.gov/pubmed/37161721 http://dx.doi.org/10.1093/cid/ciad284 |
Ejemplares similares
-
A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships
por: Goethals, Olivia, et al.
Publicado: (2023) -
Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients
por: Lachau-Durand, Sophie, et al.
Publicado: (2019) -
Bonaparte, 1769-1802 /
por: Gueniffey, Patrice
Publicado: (2018) -
Medical Lectures for 1802
Publicado: (1802) -
Donald Monro (1727–1802)
Publicado: (1971)